Advertisement
Canada markets close in 1 hour 22 minutes

  • S&P/TSX

    21,863.06
    -148.66 (-0.68%)
     

  • S&P 500

    5,063.93
    -6.62 (-0.13%)
     

  • DOW

    38,453.88
    -49.81 (-0.13%)
     

  • CAD/USD

    0.7295
    -0.0026 (-0.35%)
     

  • CRUDE OIL

    82.81
    -0.55 (-0.66%)
     

  • Bitcoin CAD

    88,628.40
    -2,871.70 (-3.14%)
     

  • CMC Crypto 200

    1,397.79
    -26.31 (-1.85%)
     

  • GOLD FUTURES

    2,334.60
    -7.50 (-0.32%)
     

  • RUSSELL 2000

    1,991.10
    -11.54 (-0.58%)
     

  • 10-Yr Bond

    4.6600
    +0.0620 (+1.35%)
     

  • NASDAQ

    15,681.91
    -14.73 (-0.09%)
     

  • VOLATILITY

    15.98
    +0.29 (+1.85%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6822
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Why Ariad Pharmaceuticals (ARIA) Stock Might be a Great Pick

Zacks Equity Research
Updated

One stock that might be an intriguing choice for investors right now is Ariad Pharmaceuticals Inc. ARIA. This is because this security in the Medicine-Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medicine-Drugs space as it currently has a Zacks Industry Rank of 44 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Ariad Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

In fact, over the past month, current quarter estimates have narrowed from a loss of 30 cents per share to a loss of 28 cents per share, while current year estimates have narrowed from a loss of $1.21 per share to a loss of $1.20 per share. The company currently holds a Zacks Rank #3 (Hold), which is also a favorable signal.

So, if you are looking for a decent pick in a strong industry, consider Ariad Pharmaceuticals. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ARIAD PHARMA (ARIA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research